Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.27 +0.19 (+0.30%)
Official Closing Price Updated: 4:15 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,516,628
Open 62.72
Bid (Size) 64.14 (1)
Ask (Size) 64.25 (4)
Prev. Close 64.08
Today's Range 62.07 - 64.30
52wk Range 64.33 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed... 
Via Benzinga
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-22.79%
-22.79%
1 Month
-4.19%
-4.19%
3 Month
-12.62%
-12.62%
6 Month
-14.74%
-14.74%
1 Year
-18.65%
-18.65%

More News

Read More
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
Is Nvidia Worth 35x Times Sales, History Says No
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
Market Whales and Their Recent Bets on GILD Options
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
Via The Motley Fool
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
3 Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
Large Cap Biopharmaceuticals Performance
Via Talk Markets
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
Why NASDAQ:GILD qualifies as a good dividend investing stock.
Via Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today
Via Benzinga
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Via Benzinga
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
Via PRLog
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Unusual Options Activity For May 06
Via Benzinga
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Via InvestorPlace
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.